BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

HealthDay News — In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 in Circulation.

Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance ...

New data show the machine learning algorithms may be used to detect PCWP elevation, aiding in assessment of heart failure with preserved ejection ...

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an ...